Minostate en es it fr

Minostate Brand names, Minostate Analogs

Minostate Brand Names Mixture

  • No information avaliable

Minostate Chemical_Formula


Minostate RX_link


Minostate fda sheet

Minostate msds (material safety sheet)

Minostate Synthesis Reference

No information avaliable

Minostate Molecular Weight

498.568 g/mol

Minostate Melting Point

No information avaliable

Minostate H2O Solubility

Soluble (about 10% weight-to-volume) in distilled water at room temperature as HCl salt.

Minostate State


Minostate LogP


Minostate Dosage Forms

Tablets (scored, coated, containing 7.5 mg or 15 mg of moexipril hydrochloride for oral administration)

Minostate Indication

For treatment of patients with hypertension.

Minostate Pharmacology

Moexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension). It works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney problems.

Minostate Absorption

Moexipril is incompletely absorbed, with bioavailability as moexiprilat of about 13% compared to intravenous (I.V.) moexipril (both measuring the metabolite moexiprilat), and is markedly affected by food, which reduces Cmax and AUC by about 70% and 40% respectively after the ingestion of a low-fat breakfast or by 80% and 50% respectively after the ingestion of a high-fat breakfast.

Minostate side effects and Toxicity

Human overdoses of moexipril have not been reported. In case reports of overdoses with other ACE inhibitors, hypotension has been the principal adverse effect noted. Single oral doses of 2 g/kg moexipril were associated with significant lethality in mice. Rats, however, tolerated single oral doses of up to 3 g/kg.

Minostate Patient Information

Minostate Organisms Affected

Humans and other mammals